Global medtech giant Medtronic has announced that it will complete the spinoff of its diabetes business within the next 18 months, creating a newly independent publicly listed company. The move reflects Medtronic’s strategic shift to concentrate on higher-growth, higher-margin areas of its business.
The new company will be headquartered in Northridge, California, retaining the diabetes unit’s existing management team and approximately 8,000 employees. It will specialize in diabetes care products including insulin pumps and continuous glucose monitoring (CGM) systems. In fiscal year 2024, the division generated \$2.8 billion in revenue, marking a 10.7% year-over-year increase.
Medtronic stated that the spinoff will give the diabetes business greater strategic flexibility and focus, allowing it to better serve the rapidly growing global diabetic population. Meanwhile, Medtronic will channel resources into its traditional strengths, such as cardiovascular, neuromodulation, and minimally invasive surgery platforms.
Medtronic CEO Geoff Martha said in a statement: This decision is about unlocking the potential of both companies, enabling them to respond more nimbly to market and regulatory demands while driving innovation. He added that the independent diabetes company would pursue a more entrepreneurial growth path and accelerate the launch of next-generation closed-loop insulin delivery systems.
Industry analysts view the spinoff as part of a broader global trend of healthcare companies restructuring operations to boost efficiency while offering capital markets new investment opportunities. Investor response was positive, with Medtronic shares rising nearly 3% on the day of the announcement.
About Medtronic
Headquartered in Dublin, Ireland, Medtronic employs more than 90,000 people worldwide and is one of the largest medical technology companies in the world. Its products are available in over 150 countries, spanning cardiovascular devices, surgical robotics, spinal and neuromodulation technologies, and more, with a mission to improve patient outcomes through technological innovation.
